Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Sees Significant Decline in Short Interest

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totaling 1,438 shares, a drop of 16.9% from the November 30th total of 1,731 shares. Approximately 1.3% of the company’s stock are short sold. Based on an average daily volume of 1,058 shares, the short-interest ratio is currently 1.4 days. Based on an average daily volume of 1,058 shares, the short-interest ratio is currently 1.4 days. Approximately 1.3% of the company’s stock are short sold.

Amplify Weight Loss Drug & Treatment ETF Trading Down 0.8%

Shares of THNR traded down $0.20 during mid-day trading on Wednesday, hitting $25.25. The company’s stock had a trading volume of 4,512 shares, compared to its average volume of 1,965. The company’s 50-day moving average is $24.80 and its 200-day moving average is $23.73. Amplify Weight Loss Drug & Treatment ETF has a 52-week low of $18.56 and a 52-week high of $26.30. The firm has a market capitalization of $2.78 million, a price-to-earnings ratio of 24.31 and a beta of 0.61.

Amplify Weight Loss Drug & Treatment ETF Dividend Announcement

The business also recently declared an annual dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Tuesday, December 30th will be given a $0.4132 dividend. This represents a dividend yield of 162.0%. The ex-dividend date of this dividend is Tuesday, December 30th.

Hedge Funds Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC raised its position in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,891 shares of the company’s stock after buying an additional 1,215 shares during the quarter. Jane Street Group LLC owned about 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent reporting period.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.